论文部分内容阅读
目的评价泽菲联合盖诺治疗不能耐受顺铂的中晚期非小细胞肺癌的疗效和毒性反应。方法74例中晚期非小细胞肺癌既往均未曾放疗或化疗。PS评分≤3分,生存期超过3个月,随机分为GN组25例(泽菲联合盖诺),NP组24例(盖诺加顺铂),GP组25例(泽菲加顺铂)。结果GN组、NP组和GP组有效率分别为44.0%、37.5%和44.0%,差异无显著性(P>0.05)。GN组与另两组在Ⅲ、Ⅳ度血液学毒性方面比较差异无显著性(P>0.05),GN组非血液学毒性比较少(P<0.05)。结论GN方案疗效较好且毒性较低,故尤其适合于不能耐受顺铂的晚期非小细胞肺癌患者。
Objective To evaluate the curative effect and toxicity of metalaxyl combined with gynol in advanced non-small cell lung cancer (NSCLC) that can not tolerate cisplatin. Methods 74 cases of advanced non-small cell lung cancer have not been previously treated with radiotherapy or chemotherapy. PS score ≤ 3 points, survival of more than 3 months, were randomly divided into 25 cases of GN (Zeffey combined ganoderma), NP group of 24 cases (ganodeca plus platinum), 25 cases of GP group ). Results The effective rates of GN group, NP group and GP group were 44.0%, 37.5% and 44.0% respectively, with no significant difference (P> 0.05). There was no significant difference in grade Ⅲ and Ⅳ hematological toxicity between GN group and other two groups (P> 0.05). GN group had less hematological toxicity (P <0.05). Conclusion GN regimen has good curative effect and low toxicity, so it is especially suitable for patients with advanced non-small cell lung cancer who can not tolerate cisplatin.